0.0951USD-4.90%Mkt Cap: 19.33M USDP/E: 0.15Last update: 2026-05-26
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine th…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap19.33M USD
Enterprise Value13.89M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)149.05M USD
Revenue/Share—
Last Price0.0951 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.15
P/E (Forward)-0.08
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.77
EPS (TTM)0.64
EPS (Forward)-1.24
52W Range
0.015059% of range0.1500
52W High0.1500 USD
52W Low0.0150 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE2275.21%
ROA2071.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.05M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-14.26%
Net Debt-5.50M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.31
Quick Ratio4.82
Book Value/Sh0.0530 USD
Cash/Share0.0340 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.160.43M
Float97.01M
Insiders24.23%
Institutions3.71%
Short Interest
Short Ratio1.2d
Short % Float5.28%
Short % Out.3.90%
Shares Short2.12M
Short (prev mo.)2.66M
Technical
SMA 500.0738 (+28.9%)
SMA 2000.0362 (+162.5%)
Beta2.64
S&P 52W Chg28.31%
Avg Vol (30d)578.13K
Avg Vol (10d)70.04K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—